Compare Quest Diagnostics Inc (DGX) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Rigetti Computing Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Rigetti Computing Inc trades at $18.49 (market cap $6.04B). The key difference: Quest Diagnostics Inc is far larger — about 4.3× Rigetti Computing Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| DGX | RGTI | |
|---|---|---|
Market Cap | $26.21B | $6.04B |
Sector | Health | Technology |
52-Week High | $238.50 | $56.34 |
52-Week Low | $173.49 | $12.90 |
Enterprise Value | $31.97B | $5.65B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Rigetti Computing (RGTI) trades at $18.42, up 4.36% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported Q2 2026 revenue growth of 185% to $5.1 million, beating estimates, but posted a net loss of $0.05 per share, missing expectations. Despite heavy operating losses and negative margins, analyst sentiment remains strongly positive with 85.7% recommending Buy, driven by government backing and quantum computing potential.
The outlook for RGTI is high-risk, high-reward, offering exposure to the emerging quantum computing sector with significant government and commercial interest. However, persistent negative profitability, high cash burn, and intense competition from peers like IonQ pose substantial risks to shareholder value. Investment suitability is limited to those tolerant of speculative, early-stage company volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
